Gebasaxturev

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

MelanomaNeoplasm MetastasisStage IIIB or IIIC or IIID melanoma

Phase 1

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

CompletedNCT04303169

Merck Sharp & Dohme LLCMelanoma

Start: 2020-06-26End: 2025-09-24Updated: 2025-10-27

A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

TerminatedNCT04521621

Merck Sharp & Dohme LLCNeoplasm Metastasis

Start: 2020-10-28End: 2023-07-25Updated: 2024-10-01

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C

CompletedCTIS2023-506314-51-00

Merck Sharp & Dohme LLCStage IIIB or IIIC or IIID melanoma

Start: 2020-07-31End: 2025-09-09Target: 29Updated: 2025-09-09

Related Papers

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial

Universität Zürich, ZORA2025-01-07

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

Nature Medicine2025-01-0123 citations

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Cancer Research2023-04-1419 citations

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.

2022-11-2929 citations

Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification

Human Gene Therapy2022-04-076 citations

426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma

Regular and Young Investigator Award Abstracts2020-11-011 citations